Search Results

MODIFIED FACTOR XA POLYPEPTIDES TO RECOVER CLOTTING ACTIVITY IN SUBJECTS TREATED WITH DIRECT ORAL ANTICOAGULANTS (DOACS)

• Source: States News Service. September 20, 2022

Record details

ONDEXXYA APPROVED IN JAPAN FOR REVERSAL OF ACUTE MAJOR BLEEDS IN PATIENTS ON FACTOR XA INHIBITORS

• Source: States News Service. March 29, 2022

Record details

Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa

• Authors : Waxman, Lloyd; Smith, Donna E.; Arcuri, Karen E.

• Source: Science. May 4, 1990, Vol. 248 Issue 4955, p593, 4 p. diagnostic image, table, diagram

Record details

Thrombosis Drugs Market Outlook 2020-2025 - Factor Xa Inhibitor Segment Expected to Register Significant Growth.

• Source: PR Newswire. July 15, 2020

Record details

CytoSorb is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery.

• Source: PR Newswire. May 12, 2020

Record details

Portola Pharmaceuticals Announces Results Demonstrating Andexxa was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds.

• Source: PR Newswire. March 16, 2020

Record details

New Data Demonstrates Andexxa Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors.

• Source: PR Newswire. March 5, 2020

Record details

Portola Pharmaceuticals Presents New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa in Patients with Acute Gastrointestinal Bleeding.

• Source: PR Newswire. Oct 28, 2019

Record details

Portola Pharmaceuticals Presents New In Vitro Data Demonstrating that Four-Factor Prothrombin Complex Concentrates (4F-PCCs) Had No Direct Effect on Inhibition of Thrombin Generation by Factor Xa Inhibitors.

• Source: PR Newswire. July 8, 2019

Record details

Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes

• Source: PR Newswire. Sept 2, 2014

Record details